Functional precision oncology to increase clinical trial success rates

  • The Patient Selection Problem: Current biomarker-based strategies identify <30% of likely responders, leading to high failure rates and inefficient trial designs.
  • The SAGE Oncotest Advantage: A best-in-class ex vivo functional profiling platform that tests patient-derived tumor cells directly against the investigational drug to identify true responders.
  • Smarter Trial Design: Incorporating functional profiling to enrich responders into the study, thereby reducing required sample size while increasing clinical trial success rates